MASP-1/2/3 Inhibitor Compositions for Early Complement Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors, such as Eculizumab, target downstream molecules and do not effectively inhibit the initiation steps of complement activation, leading to potential host tissue damage in various disease states, while the roles of the lectin and alternative pathways in these conditions are not fully understood.
Innovation Solution
Development of MASP-3 and MASP-2 inhibitory agents to target the initiation steps of the lectin and alternative complement pathways, providing a method to inhibit complement activation in conditions like PNH, AMD, ischemia-reperfusion injury, and other diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If downstream complement inhibitors like Eculizumab are used, then complement-mediated tissue damage is reduced, but the initiation steps of complement activation are not inhibited, leading to potential host tissue damage
Solution Approach 1:
The patent extracts and targets the specific initiation molecules (MASP-1, MASP-2, MASP-3) from the complement cascade, rather than using broad downstream inhibition. This selective extraction allows inhibition at the precise point where complement activation initiates, preventing both protective and harmful complement activities from occurring downstream.
Solution Approach 2:
The invention applies preliminary action by blocking MASP enzymes before the complement cascade fully activates. By inhibiting MASP-1/2/3 at the initiation stage, the patent prevents the formation of C3 convertase and subsequent C3 activation, thereby stopping the cascade before harmful effects can occur while still allowing controlled immune responses.
2Object-affected harmful factors
If C5 is blocked to inhibit complement effector molecules, then downstream complement effects are reduced, but activation of the complement system is not inhibited
Solution Approach 1:
The patent applies preliminary action by blocking MASP enzymes before the complement cascade fully activates. By inhibiting MASP-1/2/3 at the initiation stage, the patent prevents the formation of C3 convertase and subsequent C3 activation, thereby stopping the cascade before harmful effects can occur while still allowing controlled immune responses.
Solution Approach 2:
The invention uses MASP inhibitors as intermediary agents that specifically block the lectin pathway initiation without affecting other immune mechanisms. This intermediary approach allows selective inhibition of harmful complement activation while preserving other protective immune functions that do not depend on the lectin pathway.
3Adaptability or versatility
If lectin and alternative pathway roles are not fully understood, then targeted inhibition strategies are limited, but comprehensive complement inhibition is achieved
Solution Approach 1:
The patent segments the complement system into distinct pathways (lectin and alternative) and targets specific enzymes (MASP-1, MASP-2, MASP-3) within these pathways. This segmentation allows for pathway-specific inhibition strategies that can be tailored to different disease conditions while maintaining reliable inhibition of harmful complement activation.
Solution Approach 2:
The invention applies local quality by developing inhibitors with specific affinity for different MASP enzymes (MASP-1, MASP-2, MASP-3) based on their distinct roles in complement activation. This localized targeting allows optimization of inhibition strategies for specific disease states where particular MASP enzymes are primarily responsible for pathological complement activation.
Data Source
AI summary
In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.